CERS

Cerus Corporation Press Releases

$3.97
*  
0.20
4.8%
Get CERS Alerts
*Delayed - data as of Apr. 1, 2015  -  Find a broker to begin trading CERS now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    CERS After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By















Ash Stevens to Manufacture Amotosalen Active Pharmaceutical Ingredient for Cerus' INTERCEPT Blood System
1/28/2015 8:00:00 AM - PR Newswire
▼-25.93 % Price Change since this news event. The Volume Ratio is 1.01.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Cerus Prices $70.0 Million Public Offering of Common Stock
1/7/2015 8:00:00 AM - Business Wire
▼-30.72 % Price Change since this news event. The Volume Ratio is 4.81.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Cerus Announces Proposed Public Offering of Common Stock
1/5/2015 4:01:00 PM - Business Wire
▼-39.20 % Price Change since this news event. The Volume Ratio is 2.09.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Cerus Reports EU Phase 3 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint
1/5/2015 7:45:00 AM - Business Wire
▼-38.92 % Price Change since this news event. The Volume Ratio is 2.06.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day